Vext Science (FRA:VV5) LT-Debt-to-Total-Asset: 0.22 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VV5 Vext Science Inc FRA:VV5
62 GF Score
Price €0.09
GF Value €0.92
! 3 Warning Signs
View Full Analysis

What is Vext Science LT-Debt-to-Total-Asset?

Vext Science FRA:VV5 -36.03% 62 LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus rates FRA:VV5 with a GF Score™ of 62/100 and a GF Value™ of €0.92. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vext Science's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.22.

Vext Science's long-term debt to total assets ratio declined from Mar. 2025 (0.25) to Mar. 2026 (0.22). It may suggest that Vext Science is progressively becoming less dependent on debt to grow their business.

Vext Science  (FRA:VV5) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vext Science LT-Debt-to-Total-Asset Related Terms

Vext Science LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Vext Science's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vext Science LT-Debt-to-Total-Asset Chart

Vext Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.09 0.27 0.22 0.25 0.22

Vext Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.24 0.25 0.22 0.22
FRA:VV5
62GF Score
Vext Science Inc FRA:VV5
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vext Science LT-Debt-to-Total-Asset Calculation

Vext Science's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=22.75/102.932
=0.22

Vext Science's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=22.138/101.36
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.22 mean?
Vext Science (FRA:VV5) has a LT-Debt-to-Total-Asset of 0.22 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vext Science and its competitors.
Is Vext Science's LT-Debt-to-Total-Asset too high?
Vext Science's current LT-Debt-to-Total-Asset is 0.22. Overall, Vext Science has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Vext Science's LT-Debt-to-Total-Asset of 0.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vext Science and its competitors. Vext Science's current LT-Debt-to-Total-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current LT-Debt-to-Total-Asset of 0.22. The stock's GF Value™ is €0.92, compared to a current price of €0.09 — trading 90.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.22. Vext Science's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current LT-Debt-to-Total-Asset is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (FRA:VV5) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of €0.09 is trading 90.5% below its estimated GF Value™ of €0.92.

Key valuation signals for FRA:VV5:

  • LT-Debt-to-Total-Asset: 0.22
  • GF Value™: €0.92 vs. price of €0.09 (90.5% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Other Exchanges VEXTF:USAVEXT:Canada
Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
62GF Score

Get the complete analysis for FRA:VV5

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.92
GF Value